Alnylam
Navigation Links
Alnylam in Medical News
PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
MONTEREY, Calif., Dec. 13 /PRNewswire/ -- PARI's eFlow, an advanced electronic nebulizer, was optimized and used to deliver Alnylam's ALN-RSV01 in a Phase I human clinical trial. Results of the Phase I trial were announced today at the 18th Annual Drug Delivery to the Lungs meeting held in Edi...Isis to Receive $4.6 Million From Alnylam
CARLSBAD, Calif., May 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that it will receive $4.6 million dollars from Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ) as its portion of the upfront fees in the recently announced transaction between Takeda P...Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference
... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera......axis of delayed graft function after kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling precl...
aTyr Pharma Raises an Additional $12 Million
...ng and leading many successful biotechnology companies, including Alkermes, alnylam Pharmaceuticals, Cubist Pharmaceuticals, Momenta Pharmaceuticals and Sirtri...ealth Services, Advanced Inhalation Research, Akamai Technologies, Allaire, alnylam Pharmaceuticals, American Superconductor, Aspect Medical Systems, Avici Sys...Webcast Alert: Isis Pharmaceuticals' Second Quarter 2009 Financial Results Conference Call
... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...I-Therapeutix, Inc. Closes $15 Million Financing
...companies. Polaris-backed successes in life sciences include Adnexus (sold to Bristol-Myers Squibb), Advanced Inhalation Research (sold to Alkermes), alnylam Pharmaceuticals (ALNY), Glycofi (sold to Merck), Momenta Pharmaceuticals (MNTA), and Transform Pharmaceuticals (sold to Johnson & Johnson). Curren...Isis Pharmaceuticals to Present at Jefferies' 3rd Annual Healthcare Conference
... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera......ed by Quark through the gene discovery platform BiFAR(TM). For the structure of these products, Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in IND-enabling nonclinical studies a...
Isis Pharmaceuticals to Present at Needham's 8th Annual Life Sciences Conference
... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...Alnylam in Medical Technology
PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
MONTEREY, Calif., April 17 /PRNewswire/ -- An optimized PARI eFlow platform nebulizer will be delivering Alnylam's ALN-RSV01 in a Phase II human clinical trial that has begun enrolling patients. ALN-RSV01 is a RNAi therapeutic being developed as a treatment for respiratory syncytial virus (RSV...Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
... Isis received a $375,000 milestone payment from alnylam for initiation of clinical trials on ALN-VSP. ... Isis earned milestone payments from Archemix and alnylam because each company advanced drugs that incorpora...e-stranded RNA interference (ssRNAi) technology to alnylam as part of a new strategic initiative to continue ...... neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...
Isis and Collaborators Present New Research at the ATVB Annual Conference
... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...Quark Pharmaceuticals Presents at Asia TIDES Conference
...ery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling precli......rom acute injury. QPI-1002 is a chemically modified siRNA discovered by Quark with structure covered under licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1002 was the first systemically administered siRNA in a human clinical study. About Quark Pharmaceuticals, Inc. Quark ...
...mmencement of the trial triggers a milestone payment to Quark from Pfizer, a small percentage of which is payable by Quark to Silence Therapeutics and alnylam as technology license milestone payments. The Phase II prospective, randomized, dose-ranging study is evaluating the safety and efficacy of PF-45236...
...llular integrity. The AHLi-11 active molecule was designed and patented by Quark. The Company has licenses for certain RNAi intellectual property from alnylam and Silence Therapeutics About Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on disc...
...oday publication of a study in the journal Cell by alnylam and Stanford University scientists on the role of ...ntigen recognition is poorly understood. Recently, alnylam scientists and collaborators have discovered a new...es, including cancer and viral infections. About alnylam ...
...Officer. He further added that Calando has filed for patent protection on several siRNA duplexes against the RRM2 target and has licensed patents from alnylam Pharmaceuticals to enable it to develop and commercialize an RNAi therapeutic against this target. Further information about Calando can be found at...
Alnylam in Biological News
Mechanism for the in-vivo transport of siRNA
...ying mechanisms remained obscure. Markus Stoffel, ETH Zurich Professor at the Institute for Molecular Systems Biology, together with chemists from the alnylam Company, has now succeeded in elucidating the mechanism for the uptake of siRNA in combination with fatty acids in mammals. The corresponding paper, w...Alnylam in Biological Technology
CARLSBAD, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals,
Inc. (Nasdaq: ISIS ) announces the following webcast:
What: New findings published in the journal Nature on the role of a
microRNA, known as miR-21, in heart failure
When: Monday, December 1, 2...
...ery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclin...
... Biotechonomy, Nobel Laureate Phil Sharp of MIT , Microsoft Startup Labs Managing Director Reed Sturtevant, Boston Power CEO Christina Lampe-Onnerud, alnylam Pharmaceuticals CEO John Maraganore, Boston Scientific Co-founder John Abele, and Yet-Ming Chiang, co-founder of A123Systems. Start-ups represent...
... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...
...eutics); Christina Gamba-Vitalo, Senior Director Preclinical Development at alnylam Pharmaceuticals (topic: Progress in developing siRNAs as drugs); and Patric...ure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary struct...
...development of microRNA-based therapeutics for hepatocellular carcinoma has been transferred to Regulus Therapeutics. Regulus, a joint venture between alnylam Pharmaceuticals and Isis Pharmaceuticals focused on the development of microRNA-based therapeutics, and Rosetta Genomics will continue collaborating u...
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
...r of companies achieve outstanding success. Among them are: Accordant Health Services, Acusphere, Advanced Inhalation Research (acquired by Alkermes), alnylam Pharmaceuticals, Aspect Medical Systems, Cubist Pharmaceuticals, deCODE genetics, GlycoFi (acquired by Merck), Momenta Pharmaceuticals and TransForm P......ery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclin...
... Biotechonomy, Nobel Laureate Phil Sharp of MIT , Microsoft Startup Labs Managing Director Reed Sturtevant, Boston Power CEO Christina Lampe-Onnerud, alnylam Pharmaceuticals CEO John Maraganore, Boston Scientific Co-founder John Abele, and Yet-Ming Chiang, co-founder of A123Systems. Start-ups represent...
... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...
...eutics); Christina Gamba-Vitalo, Senior Director Preclinical Development at alnylam Pharmaceuticals (topic: Progress in developing siRNAs as drugs); and Patric...ure of these products Quark has licenses from Silence Therapeutics and from alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary struct...
Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
... cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA thera...The IN VIVO Blog Selects First Annual 'Deal of the Year'
... medical device industries, have selected a Deal of the Year for 2008 -- alnylam Pharmaceuticals' RNA interference alliance with Takeda Pharmaceuticals . ... example of how it pulls off this impressive feat." "The deal allows alnylam to end the year with approximately $500 million in cash and sets the RNAi p......development of microRNA-based therapeutics for hepatocellular carcinoma has been transferred to Regulus Therapeutics. Regulus, a joint venture between alnylam Pharmaceuticals and Isis Pharmaceuticals focused on the development of microRNA-based therapeutics, and Rosetta Genomics will continue collaborating u...
Isis Reports Financial Results and Highlights for Second Quarter of 2008
...bsidiaries including: -- $2.0 million milestone payment from Bristol-Myers Squibb for a PCSK9 development candidate -- $4.6 million from alnylam Pharmaceuticals, Inc. -- $1.4 million from Antisense Therapeutics Limited -- $3.3 million from Ibis representing a 72% increase from second half o...Other TagsadoptsimplementimplementRGIRGIRGIRGIRGIRGIRGIOther Contentsvalvesvalvesvalvesvalvesvalvesvalvesvesiclesvesiclesvesiclesvesiclesvesiclesseminalseminalseminalseminalseminaltubulestubulestubulestubulesseminiferousseminiferoussensesensesensesensesensesensesensesenseneuronsneuronsneuronsneuronsneuronsneuronsneurons
(Date:11/27/2009)..., Mass., Nov. 27 GSI Gro...plier of precision technology products and semicon...ting of the Company,s shareholders has been schedu...tion of the meeting will be announced in due cours...a requisition notice from Stephen Bershad, a holde...
(Date:11/27/2009)...R, N.Y., Nov. 27 Preven...ider and fortunately every year, new vaccines are ...o all vaccines boost immunity for the same period ... shots, needed to keep immunity strong? ,, In...the American Academy of Pediatrics, Michael Pichic...
(Date:11/27/2009)...ng unprecedented medical, economic burdens, study ...News) -- The number of people with diabetes in the... 25 years, a new study predicts. , That would b...e with the disease, up from 23.7 million today. ,...with diabetes will triple, the study also warns, r...
(Date:11/27/2009)... Three new interactive anatomy education apps...ns expand health sciences learning opportunities f... Durham, NC (Vocus) November 27, 2009 -- Modalit...W), a division of Wolters Kluwer Health, today ann...tion apps on the App Store. Clemente’s Anato...
(Date:11/26/2009)...ig or too heavy can lead to strains or worse , ...re may be nothing wrong with stuffing your turkey ... same thing with your suitcase as you pack for hol...ted in 2008 in U.S. hospital emergency rooms, doct... for luggage-related injuries, such as muscle stra...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Pack Right for the Holidays to Avoid the ER 2[0] GSI Group Calls Shareholders Meeting[0] Why Some Vaccines May Require A Booster[0] Diabetes Cases Expected to Double in 25 Years[0] Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store[2] Pack Right for the Holidays to Avoid the ER
(Date:11/23/2009)...s. November 23, 2009 Applied mathematicians diss...lancifolia ), a characteristic long leaf with a sa...s along the edges. The simple cause of the lily,s ...nding during differential growthwas revealed by us...ibbons. , Haiyi Liang, a postdoctoral student at...
(Date:11/23/2009)...More than 160 participants gathered this week for ... INITIATIVE conference. This year,s topic, "Synthe...rs, and medical researchers to explore the enginee...e emerging field of synthetic biology. , Bonnie ...ceton University and this year,s conference chair,...
(Date:11/23/2009)... only swine vaccine available for the H1N1 virus h...th the virus. The vaccination marks the first time...ith the pandemic flu., Iowa State University,s H... the vaccine this summer and has been shipping pre...nd Illinois for several weeks., The latest vacci...
Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B 28R 29 49981 1Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B 28R 29 49981 2Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita based Center of Excellence with Global Convenience 28TM 29 12775 1Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita based Center of Excellence with Global Convenience 28TM 29 12775 2Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita based Center of Excellence with Global Convenience 28TM 29 12775 3Migraine Frequency Tied to Stroke Heart Attack Risk 49976 1Migraine Frequency Tied to Stroke Heart Attack Risk 49976 2Migraine Frequency Tied to Stroke Heart Attack Risk 49976 3| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |